Safety and Pharmacokinetics of Intravenous and Oral Fosmanogepix, a First-in-Class Antifungal Agent, in Healthy Volunteers
Antimicrobial Agents and Chemotherapy · 18.04.2023 · 67 (4)
DOI: 10.1128/aac.01623-22 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 18.04.2023. Verfasst von Michael R Hodges und 8 weiteren Autor:innen. Beteiligte Einrichtung: Amplyx Pharmaceuticals, Inc., San Diego, California, USA. Hauptthemen laut MEDLINE: Antifungal Agents, Invasive Fungal Infections. Die Arbeit wurde bisher 57-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Amplyx.
Abstract (Originalsprache)
Fosmanogepix (FMGX, APX001), a first-in-class, intravenous (i.v.) and oral (p.o.) antifungal prodrug candidate is currently in clinical development for the treatment of invasive fungal infections. Manogepix (MGX, APX001A), the active moiety of FMGX, interferes with cell wall synthesis by targeting fungal glycosylphosphatidylinositol-anchored cell wall transfer protein 1, thereby causing loss of cell viability.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Amplyx Pharmaceuticals, Inc., San Diego, California, USA.
- Hearts Consulting Group, LLC, Poway, California, USA.
- Pfizer Inc., Groton, Connecticut, USA.
- Kramer Consulting, LLC, North Potomac, Maryland, USA.
- ICON, Groningen, the Netherlands.
ORCID-Profile: Margaret Tawadrous
Förderung
- Amplyx
Zitieren
APA
Hodges, M. R., Ople, E., Wedel, P., Shaw, K. J., Jakate, A., Kramer, W. G., Marle, S. V., van Hoogdalem, E. J., & Tawadrous, M. (2023). Safety and Pharmacokinetics of Intravenous and Oral Fosmanogepix, a First-in-Class Antifungal Agent, in Healthy Volunteers. Antimicrobial Agents and Chemotherapy, 67(4). https://doi.org/10.1128/aac.01623-22
Vancouver
Hodges MR, Ople E, Wedel P, Shaw KJ, Jakate A, Kramer WG, et al. Safety and Pharmacokinetics of Intravenous and Oral Fosmanogepix, a First-in-Class Antifungal Agent, in Healthy Volunteers. Antimicrobial Agents and Chemotherapy. 2023;67(4). doi:10.1128/aac.01623-22
BibTeX
@article{Hodges2023,
author = {Hodges, Michael R and Ople, Eric and Wedel, Pamela and Shaw, Karen J and Jakate, Abhijeet and Kramer, William G and Marle, Sjoerd van and van Hoogdalem, Ewoud-Jan and Tawadrous, Margaret},
title = {Safety and Pharmacokinetics of Intravenous and Oral Fosmanogepix, a First-in-Class Antifungal Agent, in Healthy Volunteers},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2023},
volume = {67},
number = {4},
doi = {10.1128/aac.01623-22}
}
EUVIMED